Drug Landscape ›
Ketamine low-dose ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 10
Most-reported reactions
Abdominal Pain — 1 report (10%) Diplopia — 1 report (10%) Dizziness — 1 report (10%) Drug Ineffective — 1 report (10%) Drug Intolerance — 1 report (10%) Dysstasia — 1 report (10%) Hypoaesthesia — 1 report (10%) Metamorphopsia — 1 report (10%) Muscular Weakness — 1 report (10%) Nausea — 1 report (10%)
Source database →
Ketamine low-dose in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Ketamine low-dose approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Ketamine low-dose in United States?
Cedars-Sinai Medical Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.